Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,21487100,steady-state plasma exposure,A dose of 60 mg/kg in mice produced a human equivalent sorafenib steady-state plasma exposure of 10 μM.,Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21487100/),μM,10,297,DB00398,Sorafenib
,22549288,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) of sorafenib in combination with ILI-M was 400 mg.,A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22549288/),mg,400,3531,DB00398,Sorafenib
up to,20521052,maximum sorafenib concentrations (t(max)),"Mean changes observed after 1 cycle in BP (n = 31) and HR (n = 30) at maximum sorafenib concentrations (t(max)) were moderate (up to 11.7 mm Hg and -6.6 bpm, respectively).",A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20521052/),hg·mm,11.7,6335,DB00398,Sorafenib
,20521052,maximum sorafenib concentrations (t(max)),"Mean changes observed after 1 cycle in BP (n = 31) and HR (n = 30) at maximum sorafenib concentrations (t(max)) were moderate (up to 11.7 mm Hg and -6.6 bpm, respectively).",A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20521052/),bpm,-,6336,DB00398,Sorafenib
,20521052,maximum sorafenib concentrations (t(max)),"Mean changes observed after 1 cycle in BP (n = 31) and HR (n = 30) at maximum sorafenib concentrations (t(max)) were moderate (up to 11.7 mm Hg and -6.6 bpm, respectively).",A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20521052/),bpm,6.6,6337,DB00398,Sorafenib
,32274565,AUC(0-12 h),"Once weekly, high-dose sorafenib exposure was escalated up to a target AUC(0-12 h) of 125-150 mg/L/h, achieving a twofold higher Cmax compared to standard continuous dosing.","Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: a phase I exposure escalation study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32274565/),[mg] / [h·l],125-150,7203,DB00398,Sorafenib
,26799978,flow rate,"The analyte and IS were separated on a C18 reverse phase analytical column with 4.5 min of analytical run, at flow rate of 0.3 mL/min.",Preclinical pharmacokinetics and tissue distribution of a novel multikinase inhibitor BZG by validated UPLC-MS/MS assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26799978/),[ml] / [min],0.3,8520,DB00398,Sorafenib
,28614959,Cmax,"The results showed that the Cmax (low dose: 72.38 ± 8.76 versus 49.15 ± 5.46 ng/mL; medium dose: 178.65 ± 21.05 versus 109.31 ± 14.17 ng/mL; high dose: 332.81 ± 29.38 versus 230.86 ± 9.68 ng/mL) of sorafenib at different doses increased significantly with the pretreatment of triptolide, and while the oral clearance rate of sorafenib decreased.",The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28614959/),[ng] / [ml],72.38,8744,DB00398,Sorafenib
,28614959,Cmax,"The results showed that the Cmax (low dose: 72.38 ± 8.76 versus 49.15 ± 5.46 ng/mL; medium dose: 178.65 ± 21.05 versus 109.31 ± 14.17 ng/mL; high dose: 332.81 ± 29.38 versus 230.86 ± 9.68 ng/mL) of sorafenib at different doses increased significantly with the pretreatment of triptolide, and while the oral clearance rate of sorafenib decreased.",The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28614959/),[ng] / [ml],49.15,8745,DB00398,Sorafenib
,28614959,Cmax,"The results showed that the Cmax (low dose: 72.38 ± 8.76 versus 49.15 ± 5.46 ng/mL; medium dose: 178.65 ± 21.05 versus 109.31 ± 14.17 ng/mL; high dose: 332.81 ± 29.38 versus 230.86 ± 9.68 ng/mL) of sorafenib at different doses increased significantly with the pretreatment of triptolide, and while the oral clearance rate of sorafenib decreased.",The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28614959/),[ng] / [ml],178.65,8746,DB00398,Sorafenib
,28614959,Cmax,"The results showed that the Cmax (low dose: 72.38 ± 8.76 versus 49.15 ± 5.46 ng/mL; medium dose: 178.65 ± 21.05 versus 109.31 ± 14.17 ng/mL; high dose: 332.81 ± 29.38 versus 230.86 ± 9.68 ng/mL) of sorafenib at different doses increased significantly with the pretreatment of triptolide, and while the oral clearance rate of sorafenib decreased.",The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28614959/),[ng] / [ml],109.31,8747,DB00398,Sorafenib
,28614959,Cmax,"The results showed that the Cmax (low dose: 72.38 ± 8.76 versus 49.15 ± 5.46 ng/mL; medium dose: 178.65 ± 21.05 versus 109.31 ± 14.17 ng/mL; high dose: 332.81 ± 29.38 versus 230.86 ± 9.68 ng/mL) of sorafenib at different doses increased significantly with the pretreatment of triptolide, and while the oral clearance rate of sorafenib decreased.",The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28614959/),[ng] / [ml],332.81,8748,DB00398,Sorafenib
,28614959,Cmax,"The results showed that the Cmax (low dose: 72.38 ± 8.76 versus 49.15 ± 5.46 ng/mL; medium dose: 178.65 ± 21.05 versus 109.31 ± 14.17 ng/mL; high dose: 332.81 ± 29.38 versus 230.86 ± 9.68 ng/mL) of sorafenib at different doses increased significantly with the pretreatment of triptolide, and while the oral clearance rate of sorafenib decreased.",The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28614959/),[ng] / [ml],230.86,8749,DB00398,Sorafenib
,28614959,t1/2,The t1/2 of sorafenib increased significant (p < 0.05) from 9.02 ± 1.16 to 12.17 ± 2.95 h at low dose with the pretreatment of triptolide.,The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28614959/),h,9.02,8750,DB00398,Sorafenib
,28614959,t1/2,The t1/2 of sorafenib increased significant (p < 0.05) from 9.02 ± 1.16 to 12.17 ± 2.95 h at low dose with the pretreatment of triptolide.,The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28614959/),h,12.17,8751,DB00398,Sorafenib
,28614959,intrinsic clearance rate,"However, triptolide could significantly decrease the intrinsic clearance rate of sorafenib from 51.7 ± 6.37 to 32.4 ± 4.43 μL/min/mg protein in rat liver microsomes.",The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28614959/),[μl] / [mg·min],51.7,8752,DB00398,Sorafenib
,28614959,intrinsic clearance rate,"However, triptolide could significantly decrease the intrinsic clearance rate of sorafenib from 51.7 ± 6.37 to 32.4 ± 4.43 μL/min/mg protein in rat liver microsomes.",The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28614959/),[μl] / [mg·min],32.4,8753,DB00398,Sorafenib
,21827214,Absolute bioavailability,Absolute bioavailability in humans has been investigated only for imatinib (almost 100%) and pazopanib (14-39%; n = 3).,"Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),%,100,12901,DB00398,Sorafenib
,21827214,Absolute bioavailability,Absolute bioavailability in humans has been investigated only for imatinib (almost 100%) and pazopanib (14-39%; n = 3).,"Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),%,14-39,12902,DB00398,Sorafenib
,21827214,absolute bioavailability,"Quite low absolute bioavailability under fasted conditions is assumed for nilotinib (31%), sorafenib (50%) and sunitinib (50%).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),%,31,12903,DB00398,Sorafenib
,21827214,absolute bioavailability,"Quite low absolute bioavailability under fasted conditions is assumed for nilotinib (31%), sorafenib (50%) and sunitinib (50%).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),%,50,12904,DB00398,Sorafenib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,1.5-2.5,12905,DB00398,Sorafenib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,2.0,12906,DB00398,Sorafenib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,3,12907,DB00398,Sorafenib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,1.2-4.5,12908,DB00398,Sorafenib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,5.7-6.4,12909,DB00398,Sorafenib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,3.0-4.5,12910,DB00398,Sorafenib
,24786603,Tmax,Tmax of both TMZ and AIC was delayed from 0.75 (TMZ alone) to 1.5 h (combined TMZ/Sb).,Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24786603/),h,0.75,12948,DB00398,Sorafenib
,24786603,Tmax,Tmax of both TMZ and AIC was delayed from 0.75 (TMZ alone) to 1.5 h (combined TMZ/Sb).,Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24786603/),h,1.5,12949,DB00398,Sorafenib
,24786603,progression-free survival,"The median progression-free survival was 7.9 months (95% confidence interval (CI): 5.4-14.55), and the median overall survival was 17.8 months (95% CI: 14.7-25.6).",Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24786603/),month,7.9,12950,DB00398,Sorafenib
,24786603,overall survival,"The median progression-free survival was 7.9 months (95% confidence interval (CI): 5.4-14.55), and the median overall survival was 17.8 months (95% CI: 14.7-25.6).",Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24786603/),month,17.8,12951,DB00398,Sorafenib
,28465443,overall response rate,"The overall response rate in 24 evaluable patients at all 4 dose levels was 21% [95% confidence interval (CI), 7.1-42.2], and 25% (95% CI, 8.7-49.1) in patients with measureable disease.",Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28465443/),%,21,13170,DB00398,Sorafenib
,28465443,overall response rate,"The overall response rate in 24 evaluable patients at all 4 dose levels was 21% [95% confidence interval (CI), 7.1-42.2], and 25% (95% CI, 8.7-49.1) in patients with measureable disease.",Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28465443/),%,25,13171,DB00398,Sorafenib
,28465443,progression-free survival (PFS),"Median progression-free survival (PFS) for 24 patients evaluable for PFS was 3.8 months (95% CI, 3.2-5.6 months); median overall survival was 15.5 months (95% CI, 8.5-26.3 months).",Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28465443/),month,3.8,13172,DB00398,Sorafenib
,28465443,overall survival,"Median progression-free survival (PFS) for 24 patients evaluable for PFS was 3.8 months (95% CI, 3.2-5.6 months); median overall survival was 15.5 months (95% CI, 8.5-26.3 months).",Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28465443/),month,15.5,13173,DB00398,Sorafenib
,22666367,AUC,"On day 28, median sorafenib AUC (n = 17) was significantly higher in sarcopenic patients (102.4 mg/l.h versus 53.7 mg/l.h, p = 0.013).",Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22666367/),[mg] / [h·l],102.4,14713,DB00398,Sorafenib
,22666367,AUC,"On day 28, median sorafenib AUC (n = 17) was significantly higher in sarcopenic patients (102.4 mg/l.h versus 53.7 mg/l.h, p = 0.013).",Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22666367/),[mg] / [h·l],53.7,14714,DB00398,Sorafenib
,26477611,AUC(N-oxide,"When patients were classified by cut-off points (AUC(N-oxide:) 2.0 μg ∙ day/mL, AUC ratio: 0.13), progression-free survival was significantly longer in patients with AUC(N-oxide) ≤ 2.0 μg ∙ day/mL (P = 0.0048, log-rank test).",Monitoring Serum Levels of Sorafenib and Its N-Oxide Is Essential for Long-Term Sorafenib Treatment of Patients with Hepatocellular Carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26477611/),[d·μg·∙] / [ml],2.0,21308,DB00398,Sorafenib
,26477611,AUC ratio,"When patients were classified by cut-off points (AUC(N-oxide:) 2.0 μg ∙ day/mL, AUC ratio: 0.13), progression-free survival was significantly longer in patients with AUC(N-oxide) ≤ 2.0 μg ∙ day/mL (P = 0.0048, log-rank test).",Monitoring Serum Levels of Sorafenib and Its N-Oxide Is Essential for Long-Term Sorafenib Treatment of Patients with Hepatocellular Carcinoma. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26477611/),,0.13,21309,DB00398,Sorafenib
≤,26477611,AUC(N-oxide),"When patients were classified by cut-off points (AUC(N-oxide:) 2.0 μg ∙ day/mL, AUC ratio: 0.13), progression-free survival was significantly longer in patients with AUC(N-oxide) ≤ 2.0 μg ∙ day/mL (P = 0.0048, log-rank test).",Monitoring Serum Levels of Sorafenib and Its N-Oxide Is Essential for Long-Term Sorafenib Treatment of Patients with Hepatocellular Carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26477611/),[d·μg·∙] / [ml],2.0,21310,DB00398,Sorafenib
,23673446,serum trough concentrations,"At this time, serum trough concentrations of sorafenib and M-2 were at 5.9 and 1.1 μg/ml, respectively.",Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23673446/),[μg] / [ml],5.9,22685,DB00398,Sorafenib
,23673446,serum trough concentrations,"At this time, serum trough concentrations of sorafenib and M-2 were at 5.9 and 1.1 μg/ml, respectively.",Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23673446/),[μg] / [ml],1.1,22686,DB00398,Sorafenib
,21679004,time to progression,"The median time to progression was 15.7 months (95% CI 8.4, 23.4) and the median overall survival (OS) was 29.9 months (95% CI 20.3, not estimable).",Axitinib for the management of metastatic renal cell carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21679004/),month,15.7,22741,DB00398,Sorafenib
,21679004,overall survival (OS),"The median time to progression was 15.7 months (95% CI 8.4, 23.4) and the median overall survival (OS) was 29.9 months (95% CI 20.3, not estimable).",Axitinib for the management of metastatic renal cell carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21679004/),month,29.9,22742,DB00398,Sorafenib
,21679004,progression-free survival (PFS),"The median progression-free survival (PFS) was 7.4 months (95% CI 6.7, 11.0) and a median OS of 13.6 months (95% CI 8.4, 18.8) was achieved.",Axitinib for the management of metastatic renal cell carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21679004/),month,7.4,22743,DB00398,Sorafenib
,22752248,overall survival,Median overall survival was 25.2 months.,Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22752248/),month,25.2,27315,DB00398,Sorafenib
,31463965,IC50,"Compounds 6j, 6l, and 6d showed IC50 values of 1.23, 3.78, and 3.84 μM, respectively, against the vascular endothelial growth factor receptor-2 (VEGFR-2).","New 2,4-disubstituted-2-thiopyrimidines as VEGFR-2 inhibitors: Design, synthesis, and biological evaluation. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463965/),μM,1.23,30988,DB00398,Sorafenib
,31463965,IC50,"Compounds 6j, 6l, and 6d showed IC50 values of 1.23, 3.78, and 3.84 μM, respectively, against the vascular endothelial growth factor receptor-2 (VEGFR-2).","New 2,4-disubstituted-2-thiopyrimidines as VEGFR-2 inhibitors: Design, synthesis, and biological evaluation. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463965/),μM,3.78,30989,DB00398,Sorafenib
,31463965,IC50,"Compounds 6j, 6l, and 6d showed IC50 values of 1.23, 3.78, and 3.84 μM, respectively, against the vascular endothelial growth factor receptor-2 (VEGFR-2).","New 2,4-disubstituted-2-thiopyrimidines as VEGFR-2 inhibitors: Design, synthesis, and biological evaluation. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463965/),μM,3.84,30990,DB00398,Sorafenib
,31463965,IC50,"Most of the synthesized 2-thiouracils showed antiproliferative activity against the HepG2 cell line (hepatocellular carcinoma) in the micromolar range, for instance, 9b, 6l, 6m, 6n, and 6j displayed IC50 = 7.92, 8.35, 8.51, 9.59, and 13.06 μM, respectively, relative to sorafenib (III; IC50 = 10.99 μM).","New 2,4-disubstituted-2-thiopyrimidines as VEGFR-2 inhibitors: Design, synthesis, and biological evaluation. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463965/),μM,7.92,30991,DB00398,Sorafenib
,31463965,IC50,"Most of the synthesized 2-thiouracils showed antiproliferative activity against the HepG2 cell line (hepatocellular carcinoma) in the micromolar range, for instance, 9b, 6l, 6m, 6n, and 6j displayed IC50 = 7.92, 8.35, 8.51, 9.59, and 13.06 μM, respectively, relative to sorafenib (III; IC50 = 10.99 μM).","New 2,4-disubstituted-2-thiopyrimidines as VEGFR-2 inhibitors: Design, synthesis, and biological evaluation. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463965/),μM,8.35,30992,DB00398,Sorafenib
,31463965,IC50,"Most of the synthesized 2-thiouracils showed antiproliferative activity against the HepG2 cell line (hepatocellular carcinoma) in the micromolar range, for instance, 9b, 6l, 6m, 6n, and 6j displayed IC50 = 7.92, 8.35, 8.51, 9.59, and 13.06 μM, respectively, relative to sorafenib (III; IC50 = 10.99 μM).","New 2,4-disubstituted-2-thiopyrimidines as VEGFR-2 inhibitors: Design, synthesis, and biological evaluation. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463965/),μM,8.51,30993,DB00398,Sorafenib
,31463965,IC50,"Most of the synthesized 2-thiouracils showed antiproliferative activity against the HepG2 cell line (hepatocellular carcinoma) in the micromolar range, for instance, 9b, 6l, 6m, 6n, and 6j displayed IC50 = 7.92, 8.35, 8.51, 9.59, and 13.06 μM, respectively, relative to sorafenib (III; IC50 = 10.99 μM).","New 2,4-disubstituted-2-thiopyrimidines as VEGFR-2 inhibitors: Design, synthesis, and biological evaluation. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463965/),μM,9.59,30994,DB00398,Sorafenib
,31463965,IC50,"Most of the synthesized 2-thiouracils showed antiproliferative activity against the HepG2 cell line (hepatocellular carcinoma) in the micromolar range, for instance, 9b, 6l, 6m, 6n, and 6j displayed IC50 = 7.92, 8.35, 8.51, 9.59, and 13.06 μM, respectively, relative to sorafenib (III; IC50 = 10.99 μM).","New 2,4-disubstituted-2-thiopyrimidines as VEGFR-2 inhibitors: Design, synthesis, and biological evaluation. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463965/),μM,13.06,30995,DB00398,Sorafenib
,31463965,IC50,"Most of the synthesized 2-thiouracils showed antiproliferative activity against the HepG2 cell line (hepatocellular carcinoma) in the micromolar range, for instance, 9b, 6l, 6m, 6n, and 6j displayed IC50 = 7.92, 8.35, 8.51, 9.59, and 13.06 μM, respectively, relative to sorafenib (III; IC50 = 10.99 μM).","New 2,4-disubstituted-2-thiopyrimidines as VEGFR-2 inhibitors: Design, synthesis, and biological evaluation. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463965/),μM,10.99,30996,DB00398,Sorafenib
,31463965,IC50,"Also, compounds 6j, 9a, 6m, and 6s (IC50 = 15.21, 16.96, 17.68, and 18.15 μM, respectively) are the most potent compounds against the UO-31 cell line.","New 2,4-disubstituted-2-thiopyrimidines as VEGFR-2 inhibitors: Design, synthesis, and biological evaluation. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463965/),μM,15.21,30997,DB00398,Sorafenib
,31463965,IC50,"Also, compounds 6j, 9a, 6m, and 6s (IC50 = 15.21, 16.96, 17.68, and 18.15 μM, respectively) are the most potent compounds against the UO-31 cell line.","New 2,4-disubstituted-2-thiopyrimidines as VEGFR-2 inhibitors: Design, synthesis, and biological evaluation. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463965/),μM,16.96,30998,DB00398,Sorafenib
,31463965,IC50,"Also, compounds 6j, 9a, 6m, and 6s (IC50 = 15.21, 16.96, 17.68, and 18.15 μM, respectively) are the most potent compounds against the UO-31 cell line.","New 2,4-disubstituted-2-thiopyrimidines as VEGFR-2 inhibitors: Design, synthesis, and biological evaluation. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463965/),μM,17.68,30999,DB00398,Sorafenib
,31463965,IC50,"Also, compounds 6j, 9a, 6m, and 6s (IC50 = 15.21, 16.96, 17.68, and 18.15 μM, respectively) are the most potent compounds against the UO-31 cell line.","New 2,4-disubstituted-2-thiopyrimidines as VEGFR-2 inhibitors: Design, synthesis, and biological evaluation. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463965/),μM,18.15,31000,DB00398,Sorafenib
,21392074,clearance,"PK model parameter estimates (range) for an 80 kg patient were clearance 8.13 l h(-1) (3.6-22.3 l h(-1) ), volume 213 l (50-1000 l), mean absorption transit time 1.98 h (0.5-13 h), fraction undergoing EHC 50% and average time to gall bladder emptying 6.13 h.",Population pharmacokinetic analysis of sorafenib in patients with solid tumours. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21392074/),[l] / [h],8.13,31008,DB00398,Sorafenib
,21392074,volume,"PK model parameter estimates (range) for an 80 kg patient were clearance 8.13 l h(-1) (3.6-22.3 l h(-1) ), volume 213 l (50-1000 l), mean absorption transit time 1.98 h (0.5-13 h), fraction undergoing EHC 50% and average time to gall bladder emptying 6.13 h.",Population pharmacokinetic analysis of sorafenib in patients with solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21392074/),l,213,31009,DB00398,Sorafenib
,21392074,absorption transit time,"PK model parameter estimates (range) for an 80 kg patient were clearance 8.13 l h(-1) (3.6-22.3 l h(-1) ), volume 213 l (50-1000 l), mean absorption transit time 1.98 h (0.5-13 h), fraction undergoing EHC 50% and average time to gall bladder emptying 6.13 h.",Population pharmacokinetic analysis of sorafenib in patients with solid tumours. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21392074/),h,1.98,31010,DB00398,Sorafenib
,21392074,time to gall bladder emptying,"PK model parameter estimates (range) for an 80 kg patient were clearance 8.13 l h(-1) (3.6-22.3 l h(-1) ), volume 213 l (50-1000 l), mean absorption transit time 1.98 h (0.5-13 h), fraction undergoing EHC 50% and average time to gall bladder emptying 6.13 h.",Population pharmacokinetic analysis of sorafenib in patients with solid tumours. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21392074/),h,6.13,31011,DB00398,Sorafenib
,32436621,metabolic response rate,The metabolic response rate in FDG-PET was 17% on day 5 and 20% on day 14.,Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32436621/),%,17,31814,DB00398,Sorafenib
,32436621,metabolic response rate,The metabolic response rate in FDG-PET was 17% on day 5 and 20% on day 14.,Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32436621/),%,20,31815,DB00398,Sorafenib
,32436621,progression free survival (PFS),"Median progression free survival (PFS) and overall survival (OS) were 3.25 and 5.85 months, respectively.",Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32436621/),month,3.25,31816,DB00398,Sorafenib
,32436621,overall survival (OS),"Median progression free survival (PFS) and overall survival (OS) were 3.25 and 5.85 months, respectively.",Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32436621/),month,5.85,31817,DB00398,Sorafenib
,29563636,TTP,Phase-II: patients (N = 93) were randomised to nintedanib (n = 62) or sorafenib (n = 31); TTP was 5.5 vs.,"A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29563636/),,5.5,33221,DB00398,Sorafenib
,24365125,Objective response rates,Objective response rates were 29% (trebananib plus sorafenib) and 53% (trebananib plus sunitinib).,"A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365125/),%,29,35087,DB00398,Sorafenib
,24365125,Objective response rates,Objective response rates were 29% (trebananib plus sorafenib) and 53% (trebananib plus sunitinib).,"A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365125/),%,53,35088,DB00398,Sorafenib
,22767146,overall disease control rate,"The overall disease control rate was 61% (95% confidence interval (CI): 42.6-78.8), including three confirmed responses (12%).",Sorafenib in advanced melanoma: a critical role for pharmacokinetics? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22767146/),%,61,35637,DB00398,Sorafenib
,28983849,EE,Results showed that the average EE and DL of SRF-SLNs were 89.87 and 5.39%.,Improved Oral Bioavailability and Liver Targeting of Sorafenib Solid Lipid Nanoparticles in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28983849/),%,89.87,41343,DB00398,Sorafenib
,28983849,EE,Results showed that the average EE and DL of SRF-SLNs were 89.87 and 5.39%.,Improved Oral Bioavailability and Liver Targeting of Sorafenib Solid Lipid Nanoparticles in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28983849/),%,5.39,41344,DB00398,Sorafenib
,28983849,DL,Results showed that the average EE and DL of SRF-SLNs were 89.87 and 5.39%.,Improved Oral Bioavailability and Liver Targeting of Sorafenib Solid Lipid Nanoparticles in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28983849/),%,5.39,41345,DB00398,Sorafenib
,28983849,particle,"The average particle size, polydispersity index, and zeta potential of SRF-SLNs were 77.16 nm, 0.28, and - 18.1 mV, respectively.",Improved Oral Bioavailability and Liver Targeting of Sorafenib Solid Lipid Nanoparticles in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28983849/),nm,77.16,41346,DB00398,Sorafenib
,28983849,polydispersity index,"The average particle size, polydispersity index, and zeta potential of SRF-SLNs were 77.16 nm, 0.28, and - 18.1 mV, respectively.",Improved Oral Bioavailability and Liver Targeting of Sorafenib Solid Lipid Nanoparticles in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28983849/),mv,0.28,41347,DB00398,Sorafenib
,28983849,zeta potential,"The average particle size, polydispersity index, and zeta potential of SRF-SLNs were 77.16 nm, 0.28, and - 18.1 mV, respectively.",Improved Oral Bioavailability and Liver Targeting of Sorafenib Solid Lipid Nanoparticles in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28983849/),mv,-,41348,DB00398,Sorafenib
,28983849,zeta potential,"The average particle size, polydispersity index, and zeta potential of SRF-SLNs were 77.16 nm, 0.28, and - 18.1 mV, respectively.",Improved Oral Bioavailability and Liver Targeting of Sorafenib Solid Lipid Nanoparticles in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28983849/),mv,18.1,41349,DB00398,Sorafenib
,30503942,IC50,"The ureido analogue 6u emerged as the most potent multikinase inhibitor in the ureido series with VEGFR-2, FGFR-1 and PDGFR-b IC50 of 0.18, 0.23 and 0.10 μM, respectively.","Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30503942/),μM,0.18,46174,DB00398,Sorafenib
,30503942,IC50,"The ureido analogue 6u emerged as the most potent multikinase inhibitor in the ureido series with VEGFR-2, FGFR-1 and PDGFR-b IC50 of 0.18, 0.23 and 0.10 μM, respectively.","Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30503942/),μM,0.23,46175,DB00398,Sorafenib
,30503942,IC50,"The ureido analogue 6u emerged as the most potent multikinase inhibitor in the ureido series with VEGFR-2, FGFR-1 and PDGFR-b IC50 of 0.18, 0.23 and 0.10 μM, respectively.","Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30503942/),μM,0.10,46176,DB00398,Sorafenib
,30503942,IC50,"Whereas, the amido congener 10j emerged as the most potent multikinase inhibitor in the amide series with VEGFR-2, FGFR-1 and PDGFR-b IC50 of 0.28, 0.46 and 0.09 μM, respectively.","Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30503942/),μM,0.28,46177,DB00398,Sorafenib
,30503942,IC50,"Whereas, the amido congener 10j emerged as the most potent multikinase inhibitor in the amide series with VEGFR-2, FGFR-1 and PDGFR-b IC50 of 0.28, 0.46 and 0.09 μM, respectively.","Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30503942/),μM,0.46,46178,DB00398,Sorafenib
,30503942,IC50,"Whereas, the amido congener 10j emerged as the most potent multikinase inhibitor in the amide series with VEGFR-2, FGFR-1 and PDGFR-b IC50 of 0.28, 0.46 and 0.09 μM, respectively.","Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30503942/),μM,0.09,46179,DB00398,Sorafenib
,30503942,IC50,"While, indolinone 6u was the most potent derivative towards HepG2 cells (IC50 = 2.67 ± 0.14 μM), 6r stood out as the most potent indolinone against A498 cells (IC50 = 0.78 ± 0.02 μM).","Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30503942/),μM,2.67,46180,DB00398,Sorafenib
,30503942,IC50,"While, indolinone 6u was the most potent derivative towards HepG2 cells (IC50 = 2.67 ± 0.14 μM), 6r stood out as the most potent indolinone against A498 cells (IC50 = 0.78 ± 0.02 μM).","Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30503942/),μM,0.78,46181,DB00398,Sorafenib
,27632696,critical micelle concentration,"PAAssVES was found to self-assemble into nanomicelles with diameter of about 130 nm, and a critical micelle concentration of about 6.3 μg/mL.",In vitro and in vivo evaluation of redox-responsive sorafenib carrier nanomicelles synthesized from poly (acryic acid) -cystamine hydrochloride-D-α-tocopherol succinate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27632696/),[μg] / [ml],6.3,48128,DB00398,Sorafenib
,26709621,oral bioavailability,"However, the oral bioavailability of sorafenib tablet (Nexavar) is merely 38-49% relative to the oral solution, due to the low aqueous solubility of sorafenib and its relatively high daily dose.","Improving Oral Bioavailability of Sorafenib by Optimizing the ""Spring"" and ""Parachute"" Based on Molecular Interaction Mechanisms. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26709621/),%,38-49,49008,DB00398,Sorafenib
,25248753,t1/2,"Pharmacokinetics studies showed a t1/2, CL, Tmax, and Vss of 6.45 h, 48.28 L/h (25.56 L/h/m(2)), 0.76 h, and 191 L (100.4 L/m(2)), respectively.",A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25248753/),h,6.45,57147,DB00398,Sorafenib
,25248753,CL,"Pharmacokinetics studies showed a t1/2, CL, Tmax, and Vss of 6.45 h, 48.28 L/h (25.56 L/h/m(2)), 0.76 h, and 191 L (100.4 L/m(2)), respectively.",A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25248753/),[l] / [h],48.28,57148,DB00398,Sorafenib
,25248753,CL,"Pharmacokinetics studies showed a t1/2, CL, Tmax, and Vss of 6.45 h, 48.28 L/h (25.56 L/h/m(2)), 0.76 h, and 191 L (100.4 L/m(2)), respectively.",A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25248753/),h,0.76,57149,DB00398,Sorafenib
,25248753,Tmax,"Pharmacokinetics studies showed a t1/2, CL, Tmax, and Vss of 6.45 h, 48.28 L/h (25.56 L/h/m(2)), 0.76 h, and 191 L (100.4 L/m(2)), respectively.",A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25248753/),[l] / [h],48.28,57150,DB00398,Sorafenib
,25248753,Tmax,"Pharmacokinetics studies showed a t1/2, CL, Tmax, and Vss of 6.45 h, 48.28 L/h (25.56 L/h/m(2)), 0.76 h, and 191 L (100.4 L/m(2)), respectively.",A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25248753/),h,0.76,57151,DB00398,Sorafenib
,25248753,Vss,"Pharmacokinetics studies showed a t1/2, CL, Tmax, and Vss of 6.45 h, 48.28 L/h (25.56 L/h/m(2)), 0.76 h, and 191 L (100.4 L/m(2)), respectively.",A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25248753/),l,191,57152,DB00398,Sorafenib
,25248753,time to progression,"Median time to progression was 1.8 months, and median overall survival was 7.2 months.",A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25248753/),month,1.8,57153,DB00398,Sorafenib
,25248753,overall survival,"Median time to progression was 1.8 months, and median overall survival was 7.2 months.",A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25248753/),month,7.2,57154,DB00398,Sorafenib
,22961690,AUC(0-12 hours) at steady-state,"At 80 mg/m(2) /dose, the median AUC(0-12 hours) at steady-state was 39.5 µg hours/ml.",Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22961690/),[h·μg] / [ml],39.5,60709,DB00398,Sorafenib
,22927483,N-oxide metabolite ratio,Mean sorafenib N-oxide metabolite ratio was 0.27 ± 0.14.,Ontogeny and sorafenib metabolism. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22927483/),,0.27,62375,DB00398,Sorafenib
,22927483,N-oxide ratios,"In children of ≤10 years of age, boys had approximately 2-fold higher N-oxide ratios than girls (0.40 ± 0.15 vs. 0.22 ± 0.12, P = 0.026).",Ontogeny and sorafenib metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22927483/),,0.40,62376,DB00398,Sorafenib
,22927483,N-oxide ratios,"In children of ≤10 years of age, boys had approximately 2-fold higher N-oxide ratios than girls (0.40 ± 0.15 vs. 0.22 ± 0.12, P = 0.026).",Ontogeny and sorafenib metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22927483/),,0.22,62377,DB00398,Sorafenib
,32588123,concentration,The median sorafenib concentration was 2.91 μg/mL (range 0.74-8.8 μg/mL).,Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32588123/),[μg] / [ml],2.91,65117,DB00398,Sorafenib
,32588123,trough concentration,"From results of this study, we proposed that the target range of sorafenib may be a trough concentration of 1.40-3.45 μg/mL in patients with HCC.",Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32588123/),[μg] / [ml],1.40-3.45,65118,DB00398,Sorafenib
,27992451,response rate,The response rate was 30%.,Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27992451/),%,30,67410,DB00398,Sorafenib
,27909950,overall survival (OS),"Median overall survival (OS), progression-free survival, and time to progression (TTP) were 8.6, 2.7, and 3.8 months, respectively.","HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27909950/),month,8.6,69691,DB00398,Sorafenib
,27909950,progression-free survival,"Median overall survival (OS), progression-free survival, and time to progression (TTP) were 8.6, 2.7, and 3.8 months, respectively.","HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27909950/),month,2.7,69692,DB00398,Sorafenib
,27909950,time to progression (TTP),"Median overall survival (OS), progression-free survival, and time to progression (TTP) were 8.6, 2.7, and 3.8 months, respectively.","HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27909950/),month,3.8,69693,DB00398,Sorafenib
,27909950,response rates,"Disease control and response rates (partial responses only) were 48 and 6.6%, respectively.","HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27909950/),%,6.6,69694,DB00398,Sorafenib
,27909950,TTP,Median TTP from Child-Pugh A to B/C was 88 days.,"HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27909950/),d,88,69695,DB00398,Sorafenib
,24829759,objective response rate,The objective response rate was 21% and disease control rate was 82%.,Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24829759/),%,21,71495,DB00398,Sorafenib
,24829759,disease control rate,The objective response rate was 21% and disease control rate was 82%.,Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24829759/),,82,71496,DB00398,Sorafenib
,24829759,progression-free survival,The median progression-free survival in phase 2 was 5.6 months.,Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24829759/),month,5.6,71497,DB00398,Sorafenib
,16006586,MTD,The MTD was 400 mg twice daily.,"Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006586/),mg,400,73964,DB00398,Sorafenib
,16006586,duration of stable disease,Stable disease was achieved in 22% of patients; median duration of stable disease was 7.2 months.,"Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006586/),month,7.2,73965,DB00398,Sorafenib
,16006586,half-life,"Consistent with its observed half-life of approximately 27 h, BAY 43-9, 006 accumulated on multiple dosing.","Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006586/),h,27,73966,DB00398,Sorafenib
,25294187,overall response rate,"The overall response rate was 12 % in all patients, 26 % in melanoma, 15 % in renal cell carcinoma (RCC), 10 % in HCC, and 0 % in other patients.",Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294187/),%,12,76857,DB00398,Sorafenib
,25294187,overall response rate,"The overall response rate was 12 % in all patients, 26 % in melanoma, 15 % in renal cell carcinoma (RCC), 10 % in HCC, and 0 % in other patients.",Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294187/),%,26,76858,DB00398,Sorafenib
,25294187,overall response rate,"The overall response rate was 12 % in all patients, 26 % in melanoma, 15 % in renal cell carcinoma (RCC), 10 % in HCC, and 0 % in other patients.",Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294187/),%,15,76859,DB00398,Sorafenib
,25294187,overall response rate,"The overall response rate was 12 % in all patients, 26 % in melanoma, 15 % in renal cell carcinoma (RCC), 10 % in HCC, and 0 % in other patients.",Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294187/),%,10,76860,DB00398,Sorafenib
,25294187,overall response rate,"The overall response rate was 12 % in all patients, 26 % in melanoma, 15 % in renal cell carcinoma (RCC), 10 % in HCC, and 0 % in other patients.",Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294187/),%,0,76861,DB00398,Sorafenib
,25294187,Disease control rate,"Disease control rate (CR, PR and SD ≥8 weeks) was 58 % in all patients, 90 % in RCC, 65 % in HCC, 63 % in melanoma, 40 % in breast cancer, and 8 % in NSCLC patients.",Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294187/),%,58,76862,DB00398,Sorafenib
,25294187,Disease control rate,"Disease control rate (CR, PR and SD ≥8 weeks) was 58 % in all patients, 90 % in RCC, 65 % in HCC, 63 % in melanoma, 40 % in breast cancer, and 8 % in NSCLC patients.",Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294187/),%,90,76863,DB00398,Sorafenib
,25294187,Disease control rate,"Disease control rate (CR, PR and SD ≥8 weeks) was 58 % in all patients, 90 % in RCC, 65 % in HCC, 63 % in melanoma, 40 % in breast cancer, and 8 % in NSCLC patients.",Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294187/),%,65,76864,DB00398,Sorafenib
,25294187,Disease control rate,"Disease control rate (CR, PR and SD ≥8 weeks) was 58 % in all patients, 90 % in RCC, 65 % in HCC, 63 % in melanoma, 40 % in breast cancer, and 8 % in NSCLC patients.",Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294187/),%,63,76865,DB00398,Sorafenib
,25294187,Disease control rate,"Disease control rate (CR, PR and SD ≥8 weeks) was 58 % in all patients, 90 % in RCC, 65 % in HCC, 63 % in melanoma, 40 % in breast cancer, and 8 % in NSCLC patients.",Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294187/),%,40,76866,DB00398,Sorafenib
,17951335,progression-free survival,Median progression-free survival was 224 days and the 25th percentile of overall survival was estimated at 288 days.,"Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17951335/),d,224,78570,DB00398,Sorafenib
,17951335,overall survival,Median progression-free survival was 224 days and the 25th percentile of overall survival was estimated at 288 days.,"Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17951335/),d,288,78571,DB00398,Sorafenib
,24060438,liver-to-serum ratios,The average liver-to-serum ratios 24 hours and 72 hours after treatment were approximately 14 and 22.,Transarterial embolization with sorafenib in animal livers: a pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24060438/),,14,80160,DB00398,Sorafenib
,24060438,liver-to-serum ratios,The average liver-to-serum ratios 24 hours and 72 hours after treatment were approximately 14 and 22.,Transarterial embolization with sorafenib in animal livers: a pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24060438/),,22,80161,DB00398,Sorafenib
,21673874,overall survival (OS),"Median overall survival (OS) in the CP A group was 9.5 months, compared with 3.2 months in the CP B population.",Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21673874/),month,9.5,84829,DB00398,Sorafenib
,21673874,overall survival (OS),"Median overall survival (OS) in the CP A group was 9.5 months, compared with 3.2 months in the CP B population.",Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21673874/),month,3.2,84830,DB00398,Sorafenib
,27627050,time to progression,"Median time to progression was 2.8 months (95% confidence interval, 1.05-5.52) for group I and 3.2 months (95% confidence interval, 0.95-6.70) for group II.",Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27627050/),month,2.8,87042,DB00398,Sorafenib
,27627050,time to progression,"Median time to progression was 2.8 months (95% confidence interval, 1.05-5.52) for group I and 3.2 months (95% confidence interval, 0.95-6.70) for group II.",Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27627050/),month,3.2,87043,DB00398,Sorafenib
,30963691,TTP,Median TTP was 2.7 months (95% CI: 1.5-2.9) in Part A (n = 109) and 4.2 months (95% CI: 1.7-5.5) in Part B (n = 40).,Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30963691/),month,2.7,89075,DB00398,Sorafenib
,30963691,TTP,Median TTP was 2.7 months (95% CI: 1.5-2.9) in Part A (n = 109) and 4.2 months (95% CI: 1.7-5.5) in Part B (n = 40).,Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30963691/),month,4.2,89076,DB00398,Sorafenib
,30963691,OS,"Median OS was 7.3 months (95% CI: 4.9-10.5) in Part A and 16.8 months (95% CI: 10.5-24.4) in Part B. OS was longer in AFP responders (>20% decrease from baseline, Part A) compared to non-responders (21.5 months vs 6.8 months).",Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30963691/),,4,89077,DB00398,Sorafenib
,17095207,K(i),"In vitro, sorafenib strongly inhibited SN38 glucuronidation in human liver microsomes as indicated by a K(i) value of 2.7 micromol/l.",Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17095207/),[μM] / [l],2.7,89198,DB00398,Sorafenib
>,32201308,apparent solubility,CAGE provided excellent apparent solubility of SRF tosylate (> 500 mg/mL).,Oral delivery of sorafenib through spontaneous formation of ionic liquid nanocomplexes. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32201308/),[mg] / [ml],500,91871,DB00398,Sorafenib
,31739839,time to progression,"The treatment resulted in partial response in two patients and a stable disease status in 17 patients, and the median time to progression was 120 days for both groups.","Safety, pharmacokinetics and efficacy of donafenib in treating advanced hepatocellular carcinoma: report from a phase 1b trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31739839/),d,120,93308,DB00398,Sorafenib
,24365980,constant flow rate,"After protein precipitation with acetonitrile, sorafenib and lapatinib (internal standard) were separated using isocratic elution on a Kromasil C18 column using a mobile phase of acetonitrile and 20 mmol/L ammonium acetate in a proportion 53:47 (vol/vol) pumped at a constant flow rate of 1.2 mL/min.",Development and validation of an HPLC-UV method for sorafenib quantification in human plasma and application to patients with cancer in routine clinical practice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365980/),[ml] / [min],1.2,97302,DB00398,Sorafenib
>,24365980,Recoveries,Recoveries of sorafenib from plasma were >99% in all cases.,Development and validation of an HPLC-UV method for sorafenib quantification in human plasma and application to patients with cancer in routine clinical practice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365980/),%,99,97303,DB00398,Sorafenib
,23099651,PFS,Median PFS was 8 weeks.,Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23099651/),,8,102403,DB00398,Sorafenib
,26644411,plasma half-life,"Refametinib was readily absorbed following oral administration (plasma half-life of ∼16 hours at the MTD), and pharmacokinetic parameters displayed near-dose proportionality, with less than 2-fold accumulation after multiple dosing.","A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26644411/),h,∼16,107025,DB00398,Sorafenib
,29888206,MTD,The MTD was 200 mg in both groups.,"A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29888206/),mg,200,109100,DB00398,Sorafenib
,29888206,CIR TTP,"For nintedanib and sorafenib, respectively, the median CIR TTP was 2.8 vs.","A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29888206/),,2.8,109101,DB00398,Sorafenib
,26117830,progression-free survival,The median progression-free survival was 9.9 (95% CI 6.5-17.1) months.,Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26117830/),month,9.9,109490,DB00398,Sorafenib
,32366155,trough concentration,"Patients had a median trough concentration of 3217 ng/ml (IQR 2166-4526) and 360 ng/ml (IQR 190-593) with coefficients of variation of 65% and 146% for sorafenib and M2, respectively.",The value of sorafenib trough levels in patients with advanced hepatocellular carcinoma - a substudy of the SORAMIC trial. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32366155/),[ng] / [ml],3217,111821,DB00398,Sorafenib
,32366155,trough concentration,"Patients had a median trough concentration of 3217 ng/ml (IQR 2166-4526) and 360 ng/ml (IQR 190-593) with coefficients of variation of 65% and 146% for sorafenib and M2, respectively.",The value of sorafenib trough levels in patients with advanced hepatocellular carcinoma - a substudy of the SORAMIC trial. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32366155/),[ng] / [ml],360,111822,DB00398,Sorafenib
,32366155,trough levels,"Patients who experienced severe sorafenib-related toxicity received a lower average daily dose (551 vs 730 mg/day, p = .003), but showed no significant differences in sorafenib (3298 vs 2915 ng/ml, p = .442) or M2 trough levels (428 vs 283 ng/ml, p = .159).",The value of sorafenib trough levels in patients with advanced hepatocellular carcinoma - a substudy of the SORAMIC trial. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32366155/),[ng] / [ml],428,111823,DB00398,Sorafenib
,32366155,trough levels,"Patients who experienced severe sorafenib-related toxicity received a lower average daily dose (551 vs 730 mg/day, p = .003), but showed no significant differences in sorafenib (3298 vs 2915 ng/ml, p = .442) or M2 trough levels (428 vs 283 ng/ml, p = .159).",The value of sorafenib trough levels in patients with advanced hepatocellular carcinoma - a substudy of the SORAMIC trial. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32366155/),[ng] / [ml],283,111824,DB00398,Sorafenib
,24132922,MTD,The MTD of sorafenib was 400 mg daily.,Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24132922/),mg,400,118739,DB00398,Sorafenib
,25676869,time to progression,"In the 200-mg dose cohort, three of seven patients had stable disease and a median time to progression of 61.0 days.","Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinoma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25676869/),d,61.0,119000,DB00398,Sorafenib
,27029796,area under the mAb plasma concentration-time curve (AUC(0-7d),"For control and treated mice, no significant difference was found for the area under the mAb plasma concentration-time curve (AUC(0-7d): 1.67 × 10(3) ± 1.28 × 10(2) vs. 1.76 × 10(3) ± 1.75 × 10(2) nM × day, p = 0.51).",Sorafenib Decreases Tumor Exposure to an Anti-carcinoembryonic Antigen Monoclonal Antibody in a Mouse Model of Colorectal Cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27029796/),d·nM,1.67 × 10(3),119288,DB00398,Sorafenib
,27029796,area under the mAb plasma concentration-time curve (AUC(0-7d),"For control and treated mice, no significant difference was found for the area under the mAb plasma concentration-time curve (AUC(0-7d): 1.67 × 10(3) ± 1.28 × 10(2) vs. 1.76 × 10(3) ± 1.75 × 10(2) nM × day, p = 0.51).",Sorafenib Decreases Tumor Exposure to an Anti-carcinoembryonic Antigen Monoclonal Antibody in a Mouse Model of Colorectal Cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27029796/),d·nM,1.76 × 10(3),119289,DB00398,Sorafenib
,27029796,AUC(0-7d),"However, tumor AUC(0-7d) was reduced by 40.8% in sorafenib-treated mice relative to that observed in control mice (5.61 × 10(2) ± 4.27 × 10(1) vs. 9.48 × 10(2) ± 5.61 × 10(1) nM × day, p < 0.001).",Sorafenib Decreases Tumor Exposure to an Anti-carcinoembryonic Antigen Monoclonal Antibody in a Mouse Model of Colorectal Cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27029796/),d·nM,5.61 × 10(2),119290,DB00398,Sorafenib
,27029796,AUC(0-7d),"However, tumor AUC(0-7d) was reduced by 40.8% in sorafenib-treated mice relative to that observed in control mice (5.61 × 10(2) ± 4.27 × 10(1) vs. 9.48 × 10(2) ± 5.61 × 10(1) nM × day, p < 0.001).",Sorafenib Decreases Tumor Exposure to an Anti-carcinoembryonic Antigen Monoclonal Antibody in a Mouse Model of Colorectal Cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27029796/),d·nM,9.48 × 10(2),119291,DB00398,Sorafenib
,21768474,binding constant,"In vitro, the N-oxide potently inhibited FLT3-internal tandem duplication (ITD; binding constant, 70 nmol/L) and the viability of five AML cell lines.",Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21768474/),[nM] / [l],70,125556,DB00398,Sorafenib
,23143218,apparent oral clearance,Median day 1 cyclophosphamide apparent oral clearance was 3.13 L/h/m(2).,"Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23143218/),[h·l] / [m(2],3.13,126459,DB00398,Sorafenib
,23143218,apparent oral clearance,"Median day 1 sorafenib apparent oral clearance was 44 and 39 mL/min/m(2) at the 2 dose levels evaluated, and steady-state concentrations ranged from 1.64 to 4.8 mg/L.","Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23143218/),[min·ml] / [m(2],44,126460,DB00398,Sorafenib
,23143218,apparent oral clearance,"Median day 1 sorafenib apparent oral clearance was 44 and 39 mL/min/m(2) at the 2 dose levels evaluated, and steady-state concentrations ranged from 1.64 to 4.8 mg/L.","Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23143218/),[min·ml] / [m(2],39,126461,DB00398,Sorafenib
,23143218,steady-state concentrations,"Median day 1 sorafenib apparent oral clearance was 44 and 39 mL/min/m(2) at the 2 dose levels evaluated, and steady-state concentrations ranged from 1.64 to 4.8 mg/L.","Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23143218/),[mg] / [l],1.64 to 4.8,126462,DB00398,Sorafenib
,22710664,retention times,"The retention times of SKLB610 and the internal standard were 5.6 and 8.1 min, respectively.",Pharmacokinetic studies of a novel multikinase inhibitor for treating cancer by HPLC-UV. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22710664/),min,5.6,127175,DB00398,Sorafenib
,22710664,retention times,"The retention times of SKLB610 and the internal standard were 5.6 and 8.1 min, respectively.",Pharmacokinetic studies of a novel multikinase inhibitor for treating cancer by HPLC-UV. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22710664/),min,8.1,127176,DB00398,Sorafenib
,27307733,polydispersity index,"Sorafenib-LNS were prepared by nanoprecipitation and consisted of spherical particles with a uniform size distribution (164.5 nm, polydispersity index =0.202) and negative zeta potential (-11.0 mV).","In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27307733/),,0.202,127196,DB00398,Sorafenib
,27307733,drug loading (DL),The drug loading (DL) was 10.55%±0.16%.,"In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27307733/),%,10.55,127197,DB00398,Sorafenib
,21954442,MTD,The MTD was 600 mg BID for patients receiving EIASDs and 800 mg BID for those who were not.,Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21954442/),mg,600,127386,DB00398,Sorafenib
,23146956,disease control rate,The disease control rate overall was 63%.,Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23146956/),%,63,129196,DB00398,Sorafenib
,19760364,area under the curve [AUC],"Eligible patients received paclitaxel (200 mg/m(2)) and carboplatin (area under the curve [AUC]of 6 mg min mL(-1)) on day 1 and sorafenib (400 mg, twice daily) on days 2 through 19 of a 21-day cycle.",Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19760364/),[mg·min] / [ml],6,129762,DB00398,Sorafenib
,19760364,AUC,The present study confirmed that sorafenib at 400 mg once daily in combination with carboplatin AUC 5 mg min mL(-1) and paclitaxel 200 mg/m(2) is feasible in Japanese patients with advanced NSCLC.,Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19760364/),[mg·min] / [ml],5,129763,DB00398,Sorafenib
,16908937,time to progression (TTP),"Investigator-assessed median time to progression (TTP) was 4.2 months, and median overall survival was 9.2 months.",Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16908937/),month,4.2,136066,DB00398,Sorafenib
,16908937,overall survival,"Investigator-assessed median time to progression (TTP) was 4.2 months, and median overall survival was 9.2 months.",Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16908937/),month,9.2,136067,DB00398,Sorafenib
,28741453,maximum concentration (Cmax),"The geometric mean (%CV) sorafenib maximum concentration (Cmax) without and with levothyroxine was 2.09 (68.1) and 1.78 (63.9) mg/L, respectively, with a corresponding geometric mean area under the curve of 68.1 (68.2) and 64.3 (66.3) mg·h/L. Median (range) time to Cmax was 4.00 (2.98-16.0) and 4.02 (1.98-36.0) hours, respectively.",No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),[mg] / [l],2.09,136631,DB00398,Sorafenib
,28741453,maximum concentration (Cmax),"The geometric mean (%CV) sorafenib maximum concentration (Cmax) without and with levothyroxine was 2.09 (68.1) and 1.78 (63.9) mg/L, respectively, with a corresponding geometric mean area under the curve of 68.1 (68.2) and 64.3 (66.3) mg·h/L. Median (range) time to Cmax was 4.00 (2.98-16.0) and 4.02 (1.98-36.0) hours, respectively.",No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),[mg] / [l],1.78,136632,DB00398,Sorafenib
,28741453,area under the curve,"The geometric mean (%CV) sorafenib maximum concentration (Cmax) without and with levothyroxine was 2.09 (68.1) and 1.78 (63.9) mg/L, respectively, with a corresponding geometric mean area under the curve of 68.1 (68.2) and 64.3 (66.3) mg·h/L. Median (range) time to Cmax was 4.00 (2.98-16.0) and 4.02 (1.98-36.0) hours, respectively.",No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),[h·mg] / [l],68.1,136633,DB00398,Sorafenib
,28741453,area under the curve,"The geometric mean (%CV) sorafenib maximum concentration (Cmax) without and with levothyroxine was 2.09 (68.1) and 1.78 (63.9) mg/L, respectively, with a corresponding geometric mean area under the curve of 68.1 (68.2) and 64.3 (66.3) mg·h/L. Median (range) time to Cmax was 4.00 (2.98-16.0) and 4.02 (1.98-36.0) hours, respectively.",No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),[h·mg] / [l],64.3,136634,DB00398,Sorafenib
,28741453,time to Cmax,"The geometric mean (%CV) sorafenib maximum concentration (Cmax) without and with levothyroxine was 2.09 (68.1) and 1.78 (63.9) mg/L, respectively, with a corresponding geometric mean area under the curve of 68.1 (68.2) and 64.3 (66.3) mg·h/L. Median (range) time to Cmax was 4.00 (2.98-16.0) and 4.02 (1.98-36.0) hours, respectively.",No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),h,4.00,136635,DB00398,Sorafenib
,28741453,time to Cmax,"The geometric mean (%CV) sorafenib maximum concentration (Cmax) without and with levothyroxine was 2.09 (68.1) and 1.78 (63.9) mg/L, respectively, with a corresponding geometric mean area under the curve of 68.1 (68.2) and 64.3 (66.3) mg·h/L. Median (range) time to Cmax was 4.00 (2.98-16.0) and 4.02 (1.98-36.0) hours, respectively.",No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),h,4.02,136636,DB00398,Sorafenib
,28741453,half-life,Mean (%CV) half-life was 24.0 (25.3) and 25.7 (21.0) hours.,No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),h,24.0,136637,DB00398,Sorafenib
,28741453,half-life,Mean (%CV) half-life was 24.0 (25.3) and 25.7 (21.0) hours.,No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),h,25.7,136638,DB00398,Sorafenib
,19154507,progression-free survival,"At a median potential follow-up of 27.2 months, the median progression-free survival was 3.7 months and the median overall survival was 18.0 months.",Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19154507/),month,3.7,141835,DB00398,Sorafenib
,19154507,overall survival,"At a median potential follow-up of 27.2 months, the median progression-free survival was 3.7 months and the median overall survival was 18.0 months.",Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19154507/),month,18.0,141836,DB00398,Sorafenib
,19154507,survival,For the whole trial of 46 patients the median survival was 18.3 months.,Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19154507/),month,18,141837,DB00398,Sorafenib
,22038662,AUC,"Sorafenib AUC significantly decreased over time: the median AUC during the third month of treatment was lower than that observed after one month of treatment (43.0 vs. 60.3 mg/L.h, p = 0.008).",Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22038662/),[mg] / [h·l],43.0,143283,DB00398,Sorafenib
,22038662,AUC,"Sorafenib AUC significantly decreased over time: the median AUC during the third month of treatment was lower than that observed after one month of treatment (43.0 vs. 60.3 mg/L.h, p = 0.008).",Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22038662/),[mg] / [h·l],60.3,143284,DB00398,Sorafenib
,22038662,AUC,"Most importantly, median sorafenib AUC at the time of progression was almost two-fold lower than that observed after one month of therapy (33.2 vs. 60.3 mg/L.h, p = 0.007).",Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22038662/),[mg] / [h·l],33.2,143285,DB00398,Sorafenib
,22038662,AUC,"Most importantly, median sorafenib AUC at the time of progression was almost two-fold lower than that observed after one month of therapy (33.2 vs. 60.3 mg/L.h, p = 0.007).",Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22038662/),[mg] / [h·l],60.3,143286,DB00398,Sorafenib
,21246251,response rate,"Five patients had confirmed partial response and 11 had stable disease, a response rate of 27.8%.",Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21246251/),%,27.8,146507,DB00398,Sorafenib
,29425861,EC50,"5,7-DMF significantly inhibited Bcrp1-mediated sorafenib efflux in a concentration dependent manner in MDCK/Bcrp1 cells, with EC50 value of 8.78 μM.","Effect of 5,7-dimethoxyflavone on Bcrp1-mediated transport of sorafenib in vitro and in vivo in mice. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29425861/),μM,8.78,150933,DB00398,Sorafenib
,29425861,AUC,"With 5,7-DMF, the AUC of sorafenib in plasma was 47,400 ± 4790 ng·h/mL, which was significantly higher than 27,300 ± 2650 ng·h/mL in sorafenib alone group.","Effect of 5,7-dimethoxyflavone on Bcrp1-mediated transport of sorafenib in vitro and in vivo in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29425861/),[h·ng] / [ml],"47,400",150934,DB00398,Sorafenib
higher,29425861,AUC,"With 5,7-DMF, the AUC of sorafenib in plasma was 47,400 ± 4790 ng·h/mL, which was significantly higher than 27,300 ± 2650 ng·h/mL in sorafenib alone group.","Effect of 5,7-dimethoxyflavone on Bcrp1-mediated transport of sorafenib in vitro and in vivo in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29425861/),[h·ng] / [ml],"27,300",150935,DB00398,Sorafenib
,22307138,IC(50),Sorafenib exhibited mixed-mode inhibition of UGT1A1-mediated bilirubin glucuronidation (IC(50) = 18 μmol/L; K(i) = 11.7 μmol/L) in vitro.,Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22307138/),[μM] / [l],18,152703,DB00398,Sorafenib
,22307138,K(i),Sorafenib exhibited mixed-mode inhibition of UGT1A1-mediated bilirubin glucuronidation (IC(50) = 18 μmol/L; K(i) = 11.7 μmol/L) in vitro.,Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22307138/),[μM] / [l],11.7,152704,DB00398,Sorafenib
,25835078,uptake,"Sorafenib uptake within liver tumor and nontumorous liver tissue peaked at mean 3.53 and 0.75 μg/mL, respectively, immediately post-procedure (5:1 tumor to normal tissue drug uptake ratio), before decreasing with a 10-18 hour half-life.",Pharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25835078/),[μg] / [ml],3.53,165605,DB00398,Sorafenib
,25835078,uptake,"Sorafenib uptake within liver tumor and nontumorous liver tissue peaked at mean 3.53 and 0.75 μg/mL, respectively, immediately post-procedure (5:1 tumor to normal tissue drug uptake ratio), before decreasing with a 10-18 hour half-life.",Pharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25835078/),[μg] / [ml],0.75,165606,DB00398,Sorafenib
,25835078,half-life,"Sorafenib uptake within liver tumor and nontumorous liver tissue peaked at mean 3.53 and 0.75 μg/mL, respectively, immediately post-procedure (5:1 tumor to normal tissue drug uptake ratio), before decreasing with a 10-18 hour half-life.",Pharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25835078/),h,10-18,165607,DB00398,Sorafenib
,25835078,half-life,"Serum sorafenib levels peaked immediately after TACE at a mean value of 58.58 μg/mL before normalizing with a 5.2-hour half-life, suggesting early drug washout from liver into the systemic circulation.",Pharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25835078/),h,5.2,165608,DB00398,Sorafenib
,27681866,overall survival,The median overall survival was 14.4 months.,"A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27681866/),month,14.4,166513,DB00398,Sorafenib
,27681866,MTD,The MTD of selumetinib was 75 mg daily when combined with sorafenib 400 mg twice a day in CP ≤7 HCC.,"A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27681866/),mg,75,166514,DB00398,Sorafenib
,22805325,prostatic serum antigen,The median age was 73 (57-89); median prostatic serum antigen was 284 ng ml(-1) (11.7-9027).,Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22805325/),[ng] / [ml],284,167818,DB00398,Sorafenib
,22805325,time to progression,Median time to progression was 2 months (1-5).,Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22805325/),month,2,167819,DB00398,Sorafenib
,21695438,PFS,"After a median follow-up duration of 8.6 months (range, 3.7-14.2 months), median PFS was 3.9 months (95% CI, 0.8-7.0 months) and median OS was 10.4 months (95% CI, 0-22.4 months).",Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21695438/),month,3.9,171646,DB00398,Sorafenib
,21695438,OS,"After a median follow-up duration of 8.6 months (range, 3.7-14.2 months), median PFS was 3.9 months (95% CI, 0.8-7.0 months) and median OS was 10.4 months (95% CI, 0-22.4 months).",Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21695438/),month,10,171647,DB00398,Sorafenib
,26207356,steady state concentration,The mean ± SD steady state concentration during cycle 1 day 15 was 6.5 ± 3.9 μg/ml (n = 10).,Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26207356/),[μg] / [ml],6.5,172028,DB00398,Sorafenib
,21367805,progression-free survival,Median progression-free survival was 6.3 months.,Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21367805/),month,6.3,174469,DB00398,Sorafenib
,22615057,progression free survival (PFS),The median progression free survival (PFS) and overall survival (OS) were 2.5 and 4.7 months respectively.,"Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22615057/),month,2.5,175046,DB00398,Sorafenib
,22615057,overall survival (OS),The median progression free survival (PFS) and overall survival (OS) were 2.5 and 4.7 months respectively.,"Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22615057/),month,4.7,175047,DB00398,Sorafenib
,31645371,PFS,"The five included patients had median PFS of 3.8 months (range, 1.7-10.8) and OS of 7.4 months (range, 1.7-25.8).",Sorafenib for Patients with Hepatocellular Carcinoma and Child-Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31645371/),month,3.8,185088,DB00398,Sorafenib
,31645371,OS,"The five included patients had median PFS of 3.8 months (range, 1.7-10.8) and OS of 7.4 months (range, 1.7-25.8).",Sorafenib for Patients with Hepatocellular Carcinoma and Child-Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31645371/),month,7.4,185089,DB00398,Sorafenib
,21350850,area under the plasma concentration-time curve from time 0 to 12 h (AUC(0-12)),"On day 28, area under the plasma concentration-time curve from time 0 to 12 h (AUC(0-12)) and maximum plasma concentration (C(max)) for sorafenib were 38.1 mg h/l and 4.9 mg/l, respectively.",Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21350850/),[h·mg] / [l],38.1,186875,DB00398,Sorafenib
,21350850,maximum plasma concentration (C(max)),"On day 28, area under the plasma concentration-time curve from time 0 to 12 h (AUC(0-12)) and maximum plasma concentration (C(max)) for sorafenib were 38.1 mg h/l and 4.9 mg/l, respectively.",Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21350850/),[mg] / [l],4.9,186876,DB00398,Sorafenib
≥,24135988,maximal sorafenib concentration,"In addition, a trend of prolonged overall survival was observed in HCC patients who achieved a maximal sorafenib concentration of ≥4.78 μg/mL during treatment compared with those who did not achieve the threshold concentration (12.0 vs. 6.5 months; log-rank p = 0.0824).",Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24135988/),[μg] / [ml],4.78,191268,DB00398,Sorafenib
,24726286,progression-free survival,"The median progression-free survival and overall survival for 25 evaluable patients were 10.6 and 12.6 months, respectively.",Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24726286/),month,10.6,192008,DB00398,Sorafenib
,24726286,overall survival,"The median progression-free survival and overall survival for 25 evaluable patients were 10.6 and 12.6 months, respectively.",Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24726286/),month,12.6,192009,DB00398,Sorafenib
,24726286,overall survival,"The median overall survival for patients with VEGF-A -2578 AA, -1498 CC, and -1154 AA versus alternate genotypes was 21.6 versus 14.7 months.",Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24726286/),month,21.6,192010,DB00398,Sorafenib
,24726286,overall survival,"The median overall survival for patients with VEGF-A -2578 AA, -1498 CC, and -1154 AA versus alternate genotypes was 21.6 versus 14.7 months.",Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24726286/),month,14.7,192011,DB00398,Sorafenib
,20706860,plasma concentration,"On day 45, sorafenib plasma concentration was stable (10.8 mg/L) before declining on days 60 and 75 (7.0 mg/L and 7.4 mg/L, respectively), which was probably related to an occurrence of grade-2 diarrhea.",Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20706860/),[mg] / [l],7.0,206263,DB00398,Sorafenib
,20706860,plasma concentration,"On day 45, sorafenib plasma concentration was stable (10.8 mg/L) before declining on days 60 and 75 (7.0 mg/L and 7.4 mg/L, respectively), which was probably related to an occurrence of grade-2 diarrhea.",Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20706860/),mg,7.4,206264,DB00398,Sorafenib
,30660839,Flow rate,Flow rate of 0. 45 mL/min with a run time of 5 min was used for separation.,Pharmacokinetic interaction study of novel combination of palbociclib and sorafenib for hepatocellular carcinoma in SD rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30660839/),[ml] / [min],0. 45,207053,DB00398,Sorafenib
,30660839,run time,Flow rate of 0. 45 mL/min with a run time of 5 min was used for separation.,Pharmacokinetic interaction study of novel combination of palbociclib and sorafenib for hepatocellular carcinoma in SD rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30660839/),min,5,207054,DB00398,Sorafenib
,23299770,overall survival,"Median overall survival in the study population, 67% of whom had received prior sorafenib, was 7.8 months, and for Child Pugh B patients (28%) it was 8.1 months.","CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23299770/),month,7.8,212192,DB00398,Sorafenib
,23299770,overall survival,"Median overall survival in the study population, 67% of whom had received prior sorafenib, was 7.8 months, and for Child Pugh B patients (28%) it was 8.1 months.","CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23299770/),%,28,212193,DB00398,Sorafenib
,23299770,overall survival,"Median overall survival in the study population, 67% of whom had received prior sorafenib, was 7.8 months, and for Child Pugh B patients (28%) it was 8.1 months.","CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23299770/),month,8.1,212194,DB00398,Sorafenib
,22319199,IC(50),CEP-32496 is a potent BRAF inhibitor in an in vitro binding assay for mutated BRAF(V600E) (K(d) BRAF(V600E) = 14 nmol/L) and in a mitogen-activated protein (MAP)/extracellular signal-regulated (ER) kinase (MEK) phosphorylation (pMEK) inhibition assay in human melanoma (A375) and colorectal cancer (Colo-205) cell lines (IC(50) = 78 and 60 nmol/L).,CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22319199/),[nM] / [l],78,213343,DB00398,Sorafenib
,22319199,IC(50),CEP-32496 is a potent BRAF inhibitor in an in vitro binding assay for mutated BRAF(V600E) (K(d) BRAF(V600E) = 14 nmol/L) and in a mitogen-activated protein (MAP)/extracellular signal-regulated (ER) kinase (MEK) phosphorylation (pMEK) inhibition assay in human melanoma (A375) and colorectal cancer (Colo-205) cell lines (IC(50) = 78 and 60 nmol/L).,CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22319199/),[nM] / [l],60,213344,DB00398,Sorafenib
>,22319199,orally bioavailable,"CEP-32496 is orally bioavailable in multiple preclinical species (>95% in rats, dogs, and monkeys) and has single oral dose pharmacodynamic inhibition (10-55 mg/kg) of both pMEK and pERK in BRAF(V600E) colon carcinoma xenografts in nude mice.",CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22319199/),%,95,213345,DB00398,Sorafenib
,30887253,bioavailability,"After single oral administration of LL01 at a dose of 10 mg/kg in SD male rats, LL01 showed acceptable PK properties with a mean bioavailability of 41%.",Tubulin colchicine site binding agent LL01 displays potent antitumor efficiency both in vitro and in vivo with suitable drug-like properties. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30887253/),%,41,214159,DB00398,Sorafenib
,32605304,AUC ratio,The AUC ratio (IISOR+MET group/IIISOR group) for sorafenib was equal to 0.6.,"Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32605304/),,0.6,214737,DB00398,Sorafenib
,28404979,steady state plasma concentration,"The steady state plasma concentration of sorafenib after 2 weeks of treatment ranged from 881 to 12,526 ng/mL.",In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28404979/),[ng] / [ml],"881 to 12,526",218581,DB00398,Sorafenib
,28404979,Objective response,Objective response and disease control rates were 17.02% and 69.14%.,In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28404979/),%,17.02,218582,DB00398,Sorafenib
,28404979,disease control rates,Objective response and disease control rates were 17.02% and 69.14%.,In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28404979/),%,69.14,218583,DB00398,Sorafenib
>,28404979,Plasma concentration,"Plasma concentration of sorafenib was >10,000 ng/mL in patients with severe ADRs, which decreased with reduction in dose or discontinuation of treatment.",In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28404979/),[ng] / [ml],"10,000",218584,DB00398,Sorafenib
,28404979,progression free survival,"After 21.2 weeks follow-up, median progression free survival was 12.3 months.",In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28404979/),month,12.3,218585,DB00398,Sorafenib
,25294897,Disease control rate,Disease control rate was 44.8% (primary efficacy analysis; n = 58).,A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294897/),%,44.8,220446,DB00398,Sorafenib
,25294897,time to progression,"Median time to progression was 122 days, median overall survival was 290 days (n = 70).",A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294897/),d,122,220447,DB00398,Sorafenib
,25294897,overall survival,"Median time to progression was 122 days, median overall survival was 290 days (n = 70).",A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294897/),d,290,220448,DB00398,Sorafenib
,20927524,limit of detection,The limit of detection is 0.25 ng/ml.,High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20927524/),[ng] / [ml],0.25,231642,DB00398,Sorafenib
above,20927524,recovery,Sorafenib recovery in spiked probes of peritoneal fluid was above 85%.,High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20927524/),%,85,231643,DB00398,Sorafenib
,27592284,flow rate,"The separation of both the analytes and internal standard was achieved on Discovery HS C18 column (250mm×4.6mm, 5μm) using Acetonitrile and TFA (0.025%) in the ratio of (65:35V/V) as the mobile phase in isocratic mode at a flow rate of 1ml/min, with a wavelength of 245nm and at a column oven temperature of 25°Cin a short run time of 12min.","A simple, rapid and sensitive RP-HPLC-UV method for the simultaneous determination of sorafenib & paclitaxel in plasma and pharmaceutical dosage forms: Application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27592284/),[ml] / [min],1,237803,DB00398,Sorafenib
,27592284,limits of,"The limits of detection (LLOD) were 5 and 10ng/ml while the limits of quantification (LLOQ) were 10 and 15ng/ml for sorafenib and paclitaxel, respectively.","A simple, rapid and sensitive RP-HPLC-UV method for the simultaneous determination of sorafenib & paclitaxel in plasma and pharmaceutical dosage forms: Application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27592284/),[ng] / [ml],5,237804,DB00398,Sorafenib
,27592284,limits of,"The limits of detection (LLOD) were 5 and 10ng/ml while the limits of quantification (LLOQ) were 10 and 15ng/ml for sorafenib and paclitaxel, respectively.","A simple, rapid and sensitive RP-HPLC-UV method for the simultaneous determination of sorafenib & paclitaxel in plasma and pharmaceutical dosage forms: Application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27592284/),[ng] / [ml],10,237805,DB00398,Sorafenib
,34060723,AUC0->12 h,Sorafenib steady-state exposures (area under the concentration curve from 0 to 12-h [AUC0->12 h ]) were simulated using published sorafenib pharmacokinetics at either a fixed dosage (90 mg/m2 /dose) or a pharmacokinetically guided dose targeting an AUC0->12 h between 20 and 55 h µg/ml.,Pharmacokinetically guided dosing of oral sorafenib in pediatric hepatocellular carcinoma: A simulation study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34060723/),[h·μg] / [ml],20 and 55,238009,DB00398,Sorafenib
,26582036,Cmax,"3. The results indicated that when the rats were pretreated with verapamil, the Cmax of sorafenib increased from 55.73 ng/ml to 87.72 ng/ml (57.40%), and the AUC(0-t) increased by approximately 58.2% when sorafenib was co-administered with verapamil.",The drug-drug interaction of sorafenib mediated by P-glycoprotein and CYP3A4. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26582036/),[ng] / [ml],55.73,240174,DB00398,Sorafenib
,26582036,Cmax,"3. The results indicated that when the rats were pretreated with verapamil, the Cmax of sorafenib increased from 55.73 ng/ml to 87.72 ng/ml (57.40%), and the AUC(0-t) increased by approximately 58.2% when sorafenib was co-administered with verapamil.",The drug-drug interaction of sorafenib mediated by P-glycoprotein and CYP3A4. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26582036/),[ng] / [ml],87.72,240175,DB00398,Sorafenib
,22787390,polydispersity index,"The polydispersity index, zeta potential, and EE were determined to be 0.25 ± 0.02, -16.37 ± 0.65 mV, and 93.49% ± 1.87%, respectively (n = 3).","Preparation, in vitro release, and pharmacokinetics in rabbits of lyophilized injection of sorafenib solid lipid nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22787390/),mv,0.25,241906,DB00398,Sorafenib
,22787390,zeta potential,"The polydispersity index, zeta potential, and EE were determined to be 0.25 ± 0.02, -16.37 ± 0.65 mV, and 93.49% ± 1.87%, respectively (n = 3).","Preparation, in vitro release, and pharmacokinetics in rabbits of lyophilized injection of sorafenib solid lipid nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22787390/),mv,-,241907,DB00398,Sorafenib
,22787390,zeta potential,"The polydispersity index, zeta potential, and EE were determined to be 0.25 ± 0.02, -16.37 ± 0.65 mV, and 93.49% ± 1.87%, respectively (n = 3).","Preparation, in vitro release, and pharmacokinetics in rabbits of lyophilized injection of sorafenib solid lipid nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22787390/),mv,16.37,241908,DB00398,Sorafenib
,22787390,EE,"The polydispersity index, zeta potential, and EE were determined to be 0.25 ± 0.02, -16.37 ± 0.65 mV, and 93.49% ± 1.87%, respectively (n = 3).","Preparation, in vitro release, and pharmacokinetics in rabbits of lyophilized injection of sorafenib solid lipid nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22787390/),mv,16.37,241909,DB00398,Sorafenib
,22787390,EE,"The polydispersity index, zeta potential, and EE were determined to be 0.25 ± 0.02, -16.37 ± 0.65 mV, and 93.49% ± 1.87%, respectively (n = 3).","Preparation, in vitro release, and pharmacokinetics in rabbits of lyophilized injection of sorafenib solid lipid nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22787390/),%,93.49,241910,DB00398,Sorafenib
,22006162,AUC,"AUC increased less than proportionally with increasing doses [47.3 (41.3-63.3), 60.3 (56.3-64.4), 71.4 (51.3-99.1), 75.9 (45.5-100.9) mg/L.h for 400, 800, 1,200 and 1,600 mg/day, respectively].",Saturable absorption of sorafenib in patients with solid tumors: a population model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22006162/),[mg] / [h·l],47.3,243433,DB00398,Sorafenib
,22006162,AUC,"AUC increased less than proportionally with increasing doses [47.3 (41.3-63.3), 60.3 (56.3-64.4), 71.4 (51.3-99.1), 75.9 (45.5-100.9) mg/L.h for 400, 800, 1,200 and 1,600 mg/day, respectively].",Saturable absorption of sorafenib in patients with solid tumors: a population model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22006162/),[mg] / [h·l],60.3,243434,DB00398,Sorafenib
,22006162,AUC,"AUC increased less than proportionally with increasing doses [47.3 (41.3-63.3), 60.3 (56.3-64.4), 71.4 (51.3-99.1), 75.9 (45.5-100.9) mg/L.h for 400, 800, 1,200 and 1,600 mg/day, respectively].",Saturable absorption of sorafenib in patients with solid tumors: a population model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22006162/),[mg] / [h·l],71.4,243435,DB00398,Sorafenib
,22006162,AUC,"AUC increased less than proportionally with increasing doses [47.3 (41.3-63.3), 60.3 (56.3-64.4), 71.4 (51.3-99.1), 75.9 (45.5-100.9) mg/L.h for 400, 800, 1,200 and 1,600 mg/day, respectively].",Saturable absorption of sorafenib in patients with solid tumors: a population model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22006162/),[mg] / [h·l],75.9,243436,DB00398,Sorafenib
,22006162,AUC,"According to the simulations, dividing the daily dose in three or four doses for daily dose >800 mg would significantly increase AUC compared with a twice daily dosing regimen (101.7 vs 81.6 mg/L.h for 400 mg q8h and 600 mg q12h respectively; 131.6 vs 91.5 mg/L.h for 400 mg q6h and 800 mg q12h, respectively).",Saturable absorption of sorafenib in patients with solid tumors: a population model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22006162/),[mg] / [h·l],101.7,243437,DB00398,Sorafenib
,22006162,AUC,"According to the simulations, dividing the daily dose in three or four doses for daily dose >800 mg would significantly increase AUC compared with a twice daily dosing regimen (101.7 vs 81.6 mg/L.h for 400 mg q8h and 600 mg q12h respectively; 131.6 vs 91.5 mg/L.h for 400 mg q6h and 800 mg q12h, respectively).",Saturable absorption of sorafenib in patients with solid tumors: a population model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22006162/),[mg] / [h·l],81.6,243438,DB00398,Sorafenib
,22006162,AUC,"According to the simulations, dividing the daily dose in three or four doses for daily dose >800 mg would significantly increase AUC compared with a twice daily dosing regimen (101.7 vs 81.6 mg/L.h for 400 mg q8h and 600 mg q12h respectively; 131.6 vs 91.5 mg/L.h for 400 mg q6h and 800 mg q12h, respectively).",Saturable absorption of sorafenib in patients with solid tumors: a population model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22006162/),[mg] / [h·l],131.6,243439,DB00398,Sorafenib
,22006162,AUC,"According to the simulations, dividing the daily dose in three or four doses for daily dose >800 mg would significantly increase AUC compared with a twice daily dosing regimen (101.7 vs 81.6 mg/L.h for 400 mg q8h and 600 mg q12h respectively; 131.6 vs 91.5 mg/L.h for 400 mg q6h and 800 mg q12h, respectively).",Saturable absorption of sorafenib in patients with solid tumors: a population model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22006162/),[mg] / [h·l],91.5,243440,DB00398,Sorafenib
,20395213,nonprogression rate,The nonprogression rate at 6 weeks was 74%: 12 (24%) partial response and 25 (50%) stable disease.,A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20395213/),%,74,244829,DB00398,Sorafenib
,20395213,time to progression,"Median time to progression was 5.0 months [95% confidence interval (95% CI), 3.2-6.8 months].",A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20395213/),month,5.0,244830,DB00398,Sorafenib
,20395213,overall survival,"Median overall survival was 10.9 months (95% CI, 3.8-18.1 months).",A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20395213/),month,10.9,244831,DB00398,Sorafenib
,31295152,time-to-tumor progression,"For the 150 mg b.i.d. galunisertib cohort, the median time-to-tumor progression was 4.1 months; the median OS was 18.8 months.",A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31295152/),month,4.1,247113,DB00398,Sorafenib
,31295152,OS,"For the 150 mg b.i.d. galunisertib cohort, the median time-to-tumor progression was 4.1 months; the median OS was 18.8 months.",A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31295152/),month,18.8,247114,DB00398,Sorafenib
,15870716,MTD,A MTD of 400 mg b.i.d. BAY 43-9006 was defined.,"Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15870716/),mg,400,250113,DB00398,Sorafenib
,27405013,GI50,"In particular, it showed GI50 values of 51.4 and 19 nm against leukemia K-562 and colon carcinoma KM12 cell lines, respectively.",Discovery of a Nanomolar Multikinase Inhibitor (KST016366): A New Benzothiazole Derivative with Remarkable Broad-Spectrum Antiproliferative Activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27405013/),nm,51.4,252750,DB00398,Sorafenib
,27405013,GI50,"In particular, it showed GI50 values of 51.4 and 19 nm against leukemia K-562 and colon carcinoma KM12 cell lines, respectively.",Discovery of a Nanomolar Multikinase Inhibitor (KST016366): A New Benzothiazole Derivative with Remarkable Broad-Spectrum Antiproliferative Activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27405013/),nm,19,252751,DB00398,Sorafenib
,27405013,IC50,"Interestingly, 6 displays IC50 values of 0.82, 3.81, and 53 nm toward Tie2, TrkA, and ABL-1 (wild-type and T315I mutant) kinases, respectively.",Discovery of a Nanomolar Multikinase Inhibitor (KST016366): A New Benzothiazole Derivative with Remarkable Broad-Spectrum Antiproliferative Activity. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27405013/),nm,0.82,252752,DB00398,Sorafenib
,27405013,IC50,"Interestingly, 6 displays IC50 values of 0.82, 3.81, and 53 nm toward Tie2, TrkA, and ABL-1 (wild-type and T315I mutant) kinases, respectively.",Discovery of a Nanomolar Multikinase Inhibitor (KST016366): A New Benzothiazole Derivative with Remarkable Broad-Spectrum Antiproliferative Activity. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27405013/),nm,3.81,252753,DB00398,Sorafenib
,27405013,IC50,"Interestingly, 6 displays IC50 values of 0.82, 3.81, and 53 nm toward Tie2, TrkA, and ABL-1 (wild-type and T315I mutant) kinases, respectively.",Discovery of a Nanomolar Multikinase Inhibitor (KST016366): A New Benzothiazole Derivative with Remarkable Broad-Spectrum Antiproliferative Activity. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27405013/),nm,53,252754,DB00398,Sorafenib
,32847973,Response rates,Response rates were 48% overall (27) and 64% for ovarian cancers (14).,"Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32847973/),%,48,252812,DB00398,Sorafenib
,32847973,Response rates,Response rates were 48% overall (27) and 64% for ovarian cancers (14).,"Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32847973/),%,64,252813,DB00398,Sorafenib
,32847973,overall,VEGF-A-1154AA and -7TT recessive homozygous genotypes conferred worse overall survival versus alternative genotypes (7 vs. 22 months).,"Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32847973/),month,7,252814,DB00398,Sorafenib
,32847973,overall,VEGF-A-1154AA and -7TT recessive homozygous genotypes conferred worse overall survival versus alternative genotypes (7 vs. 22 months).,"Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32847973/),month,22,252815,DB00398,Sorafenib
,21072558,Peak plasma concentrations,Peak plasma concentrations after IV dosing ranged from 3.4 to 7.6 μg/mL.,The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21072558/),[μg] / [ml],3.4 to 7.6,258145,DB00398,Sorafenib
,21072558,area under the plasma concentration from 0 to 24 h,"The mean ± standard deviation (SD) area under the plasma concentration from 0 to 24 h was 28 ± 4.3 μg • h/mL, which is comparable to the exposure observed in humans at recommended doses.",The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21072558/),[h·μg] / [ml],28,258146,DB00398,Sorafenib
,21072558,clearance,The mean ± SD clearance was 1.7 ± 0.5 mL/min/kg.,The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21072558/),[ml] / [kg·min],1.7,258147,DB00398,Sorafenib
,21072558,peak CSF concentrations,The peak CSF concentrations ranged from 0.00045 to 0.00058 μg/mL.,The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21072558/),[μg] / [ml],0,258148,DB00398,Sorafenib
,21072558,area under the CSF concentration from 0 to 24h,The mean ± SD area under the CSF concentration from 0 to 24h was 0.0048 ± 0.0016 μg•h/mL.,The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21072558/),[h·μg] / [ml],0.0048,258149,DB00398,Sorafenib
,21072558,CSF penetration,The mean CSF penetration of sorafenib was 0.02% and 3.4% after correcting for plasma protein binding.,The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21072558/),%,0.02,258150,DB00398,Sorafenib
,21072558,CSF penetration,The mean CSF penetration of sorafenib was 0.02% and 3.4% after correcting for plasma protein binding.,The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21072558/),%,3.4,258151,DB00398,Sorafenib
,32399603,z,"The prepared RDV-coated nanoparticles (RDV-NPs) had good stability, with a zeta potential of - 10.7 mV and particle size of 113.5 nm.",Preparation and evaluation of long circulating erythrocyte membrane-cloaked anti-cancer drug delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32399603/),mv,10.7,259035,DB00398,Sorafenib
,32399603,cumulative release,In vitro drug release investigation showed that RDV-NPs had good sustained release properties and the cumulative release was 71.5% in 72 h.,Preparation and evaluation of long circulating erythrocyte membrane-cloaked anti-cancer drug delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32399603/),%,71.5,259036,DB00398,Sorafenib
,32399603,MRT,The MRT and t1/2 of RDV-NPs were increased to 23.670 ± 2.347 h and 24.450 ± 2.652 h.,Preparation and evaluation of long circulating erythrocyte membrane-cloaked anti-cancer drug delivery system. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32399603/),h,23.670,259037,DB00398,Sorafenib
,32399603,t1/2,The MRT and t1/2 of RDV-NPs were increased to 23.670 ± 2.347 h and 24.450 ± 2.652 h.,Preparation and evaluation of long circulating erythrocyte membrane-cloaked anti-cancer drug delivery system. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32399603/),h,24.450,259038,DB00398,Sorafenib
,33553923,area under the curve,"The pharmacokinetic results demonstrated that the area under the curve of sorafenib (10 mg/kg, p.o.) in combination with various doses of H. diffusa formulation (1, 3, and 10 g/kg, p.o.) for 5 consecutive days were 5560 ± 1392, 7965 ± 2055, 7271 ± 1371, and 8821 ± 1705 min μg/mL, respectively, no significant difference when compared with sorafenib treatment alone.",Preclinical Pharmacokinetic Interaction and Histopathological Analyses of Hedyotis diffusa on Sorafenib in Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33553923/),[min·μg] / [ml],5560,260338,DB00398,Sorafenib
,33553923,area under the curve,"The pharmacokinetic results demonstrated that the area under the curve of sorafenib (10 mg/kg, p.o.) in combination with various doses of H. diffusa formulation (1, 3, and 10 g/kg, p.o.) for 5 consecutive days were 5560 ± 1392, 7965 ± 2055, 7271 ± 1371, and 8821 ± 1705 min μg/mL, respectively, no significant difference when compared with sorafenib treatment alone.",Preclinical Pharmacokinetic Interaction and Histopathological Analyses of Hedyotis diffusa on Sorafenib in Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33553923/),[min·μg] / [ml],7965,260339,DB00398,Sorafenib
,33553923,area under the curve,"The pharmacokinetic results demonstrated that the area under the curve of sorafenib (10 mg/kg, p.o.) in combination with various doses of H. diffusa formulation (1, 3, and 10 g/kg, p.o.) for 5 consecutive days were 5560 ± 1392, 7965 ± 2055, 7271 ± 1371, and 8821 ± 1705 min μg/mL, respectively, no significant difference when compared with sorafenib treatment alone.",Preclinical Pharmacokinetic Interaction and Histopathological Analyses of Hedyotis diffusa on Sorafenib in Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33553923/),[min·μg] / [ml],7271,260340,DB00398,Sorafenib
,33553923,area under the curve,"The pharmacokinetic results demonstrated that the area under the curve of sorafenib (10 mg/kg, p.o.) in combination with various doses of H. diffusa formulation (1, 3, and 10 g/kg, p.o.) for 5 consecutive days were 5560 ± 1392, 7965 ± 2055, 7271 ± 1371, and 8821 ± 1705 min μg/mL, respectively, no significant difference when compared with sorafenib treatment alone.",Preclinical Pharmacokinetic Interaction and Histopathological Analyses of Hedyotis diffusa on Sorafenib in Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33553923/),[min·μg] / [ml],8821,260341,DB00398,Sorafenib
,23328813,overall survival,The median overall survival was 5.7 months.,NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23328813/),month,5.7,261872,DB00398,Sorafenib
,23328813,Progression-free survival,Progression-free survival at 6 months was 14%.,NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23328813/),%,14,261873,DB00398,Sorafenib
less,29551745,polydispersity (PDI),"The developed SFN loaded PB-b-PEO polymersomes (SFN-PB-b-PEO, test formulation) characterized by DLS and cryo-TEM showed particle size 282 nm, polydispersity (PDI) of less than 0.29 and membrane thickness of about 20 nm.",Fabrication of poly (butadiene-block-ethylene oxide) based amphiphilic polymersomes: An approach for improved oral pharmacokinetics of Sorafenib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29551745/),,0.29,270363,DB00398,Sorafenib
,22752067,12-hour,"For 83 patients (median age, 62 years; range, 21-84 years), median sorafenib 12-hour area under the curve (AUC(0-12)) was 52.8 mg · h/L (range: 11.8-199.6).",Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22752067/),[h·mg] / [l],52.8,272989,DB00398,Sorafenib
,22752067,area under the curve (AUC(0-12)),"For 83 patients (median age, 62 years; range, 21-84 years), median sorafenib 12-hour area under the curve (AUC(0-12)) was 52.8 mg · h/L (range: 11.8-199.6).",Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22752067/),[h·mg] / [l],52.8,272990,DB00398,Sorafenib
,22752067,AUC(0-12),Sorafenib AUC(0-12) preceding grade 3-4 toxicities was significantly higher than that observed in the remaining population (61.9 mg · h/L vs. 53 mg · h/L).,Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22752067/),[h·mg] / [l],61.9,272991,DB00398,Sorafenib
,22752067,AUC(0-12),Sorafenib AUC(0-12) preceding grade 3-4 toxicities was significantly higher than that observed in the remaining population (61.9 mg · h/L vs. 53 mg · h/L).,Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22752067/),[h·mg] / [l],53,272992,DB00398,Sorafenib
,22752067,dose-normalized AUC(0-12),"In 25 patients treated with fixed doses of sorafenib for the first 4 months, median dose-normalized AUC(0-12) on day 120 was significantly lower than on day 15 (63 vs. 102 mg · h/L).",Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22752067/),[h·mg] / [l],63,272993,DB00398,Sorafenib
,22752067,dose-normalized AUC(0-12),"In 25 patients treated with fixed doses of sorafenib for the first 4 months, median dose-normalized AUC(0-12) on day 120 was significantly lower than on day 15 (63 vs. 102 mg · h/L).",Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22752067/),[h·mg] / [l],102,272994,DB00398,Sorafenib
,31967518,clearance,Patient's clearance (0.48 l/h) estimated by Bayesian approach was consistently lower than usually described.,Pharmacogenetics and pharmacokinetics modeling of unexpected and extremely severe toxicities after sorafenib intake. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31967518/),[l] / [h],0.48,273744,DB00398,Sorafenib
